Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alnylam Pharmaceuticals, Inc.
Alnylam to collaborate with U.S. Army on RNAi therapeutics for biodefense threats
May 8th, 2006
Alnylam Pharmaceuticals, Inc., (ALNY) signed a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). Under the agreement, Alnylam will collaborate with USAMRIID to discover RNAi therapeutics targeting viral organisms, including hemorrhagic fever viruses, which pose a serious biological threat to the military and public health of the United States. "USAMRIID is actively seeking promising technologies to protect our armed forces, and we believe Alnylam's RNAi therapeutic platform enables the rapid discovery and development of anti-virals designed to be broad in...
Source: Biotech Week (2006-05-08)
|
